Welcome, Guest. Please login or register.
July 14, 2024, 01:38:00 pm

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 237
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 19
Total: 19


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Disappointing Midway Trial Results for Emricasan as Treatment for NASH  (Read 9833 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Halfway through a 48-week trial, Conatus Pharmaceuticals’ emricasan showed a trend toward a lack of efficacy as treatment for non-alcoholic steatohepatitis (NASH), MedPage Today reports. While the trial must complete before a proper assessment of the drug’s efficacy can be assessed, the 24-week results are not promising.

Presenting their findings at the 53rd International Liver Congress in Vienna, researchers conducted a multicenter randomized trial at 59 sites in the United States and the European Union. The study enrolled 263 people with NASH cirrhosis and an initial hepatic venous pressure gradient (HVPG) of at least 12 millimeters of mercury (mmHg).



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.